The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

William Wierda | ASCO 2018 | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial

Jun 8, 2018

ASCO Annual Meeting, 1-5 June 2018, Chicago, IL
William Wierda
MD Anderson Cancer Center, Houston, US

Interview topic: Ibrutinib and venetoclax combination for first-line CLL: the CAPTIVATE phase II trial

William Wierda | ASCO 2018 | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial